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Investigation performed at the Catholic University of Korea School of Medicine, Seoul, Republic of Korea

Background: It is well known that age-related fibrosis, or decreases in the elastin-to-collagen ratio of the ligamentum
flavum, along with hypertrophy of the ligamentum flavum, are associated with lumbar spinal stenosis. However, the
molecular mechanism by which this fibrosis and hypertrophy develop is unknown. Tissue inhibitors of matrix metalloproteinase (TIMPs) are proteinase inhibitors that suppress extracellular matrix degradation. Elevated TIMP-1 and
TIMP-2 expression has been implicated in various fibrotic diseases of the liver, kidney, lung, and heart. These TIMPs
can also induce cellular proliferation and inhibit apoptosis in a wide range of cell types. These findings led us to postulate that TIMP-1 and TIMP-2 might also be associated with hypertrophy and fibrosis of the ligamentum flavum in
lumbar spinal stenosis.
Methods: We quantified and localized TIMP expression in ligamentum flavum tissues that had been obtained during
surgery from thirty patients with spinal stenosis and from thirty gender-matched control patients with disc herniation.
The thickness of the ligamentum flavum at the level of the facet joint was measured on axial T1-weighted magnetic
resonance images. In addition, we examined ligamentum flavum tissues for the expression of markers of cellular proliferation and apoptosis.
Results: The ligamentum flavum was significantly thicker in the patients with spinal stenosis (mean, 5.68 mm) than
in the patients with disc herniation (mean, 2.70 mm) (p < 0.001). The concentration of TIMP-2 in the ligamentum flavum was significantly higher in the patients with spinal stenosis (mean, 12.62 ng/mL) than in those with disc herniation (mean, 8.85 ng/mL) (p = 0.028). TIMP-1 and TIMP-2 were detected in the cytoplasm of ligamentum flavum
fibroblasts. TIMP-1 and TIMP-2 concentrations were associated with hypertrophy of the ligamentum flavum (p = 0.015
and p = 0.003, respectively). None of the samples from the patients with stenosis had evidence of proliferation of ligamentum flavum fibroblasts. The expression of markers for apoptosis was significantly higher in the patients with spinal stenosis (58.8%) than in those with disc herniation (26.6%) (p < 0.001).
Conclusions: Increased TIMP expression has been implicated in fibrosis and hypertrophy of the extracellular matrix
of several organs. Our results suggest that increased expression of TIMP-2 in ligamentum flavum fibroblasts is associated with fibrosis and hypertrophy of the ligamentum flavum in patients with spinal stenosis.
Clinical Relevance: Gaining insights into the molecular pathogenesis of hypertrophy and fibrosis of the ligamentum
flavum may eventually result in new therapeutic and potentially noninvasive alternatives to the treatment of spinal
stenosis.

T

he ligamentum flavum is composed of elastin and collagen fibers in a 2:1 ratio. The elastin fibers impart a yellow color to the structure and provide the elasticity, while
the collagen provides the stiffness and stability. With age, the
elastin-to-collagen ratio decreases, resulting in decreased elastic-

ity and increased stiffness or fibrosis. In addition, the ligamentum flavum hypertrophies, and the combination sometimes
results in lumbar spinal stenosis1-5. Although the hypertrophy
and fibrosis have been postulated to be due to degenerative
changes secondary to the aging process and mechanical stress sec-
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ondary to instability, the pathogenesis remains undetermined.
Matrix metalloproteinases (MMPs) are a family of more
than twenty enzymes that digest proteins in the extracellular
matrix6-9. There are also inhibitors of MMPs, called tissue inhibitors of matrix metalloproteinase (TIMPs), and it is believed that, together, MMPS and TIMPs regulate the integrity
and homeostasis of the extracellular matrix. There are four
known TIMPs (TIMP-1 through 4) that suppress extracellular matrix degradation by forming an inhibitory 1:1 complex
with the MMPs10-18. Elevated expressions of TIMP-1 and
TIMP-2 have been implicated in the increased fibrosis found
in a wide variety of human organs, including the liver, kidney,
lung, and heart. TIMPs are also known to increase cellular
proliferation19-21 and inhibit programmed cell death (apoptosis) in a wide range of cell types22-26.
On the basis of what is known about TIMPs, we hypothesized that they might also play a role in the hypertrophy of
the ligamentum flavum seen in lumbar spinal stenosis. We
postulated that TIMPs might alter the ligamentum flavum in
three ways: by increasing the density of the extracellular matrix and promoting fibrosis by inhibiting MMPs, by increasing
fibroblast proliferation, and by reducing the rate of fibroblast
apoptosis. In the present study, our goals were to determine
(1) whether there is an increased concentration of TIMPs in
the ligamentum flavum of patients with spinal stenosis compared with that in patients with disc herniation, and (2)
whether the ligamentum flavum in spinal stenosis has increased fibroblast proliferation and/or decreased apoptosis, either of which would result in increased cellularity. To our
knowledge, no one has previously investigated the association
between hypertrophy of the ligamentum flavum and concentrations of TIMP-1 and TIMP-2.
Materials and Methods
hirty samples of ligamentum flavum tissue were obtained
from thirty patients who were undergoing decompression
because of neurogenic claudication due to lumbar spinal stenosis that had been unresponsive to conservative measures for at
least three months. None of these patients received epidural or
selective nerve-root blocks. Twenty-one patients were female,
and nine were male. The mean age of the patients at the time of
surgery was 63.7 years (range, fifty-two to seventy-eight years).
Patients with degenerative spondylolisthesis were excluded
from the study. Seventeen patients underwent a one-level operation; nine, a two-level operation; and four, a three-level operation. We tried to obtain the entire layer of the central portion of
the ligamentum flavum, and we removed the epidural fat from
the ligamentum flavum tissues. Half of each ligamentum flavum specimen was fixed in 4% neutral formalin, decalcified
with 20% EDTA for six weeks, and embedded in paraffin;
the other half was kept in a freezer at −70°C for subsequent
enzyme-linked immunosorbent assay (ELISA).
We randomly selected thirty gender-matched control patients with lumbar disc herniation from a group of 124 patients
who were being operatively managed for that disorder. The
mean age of the control patients was 31.7 years (range, nineteen
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to forty-three years), which was significantly younger than the
mean age of the patients with spinal stenosis (p < 0.001).
Measurement of the Thickness
of the Ligamentum Flavum
An axial T1-weighted magnetic resonance image (repetition
time, 600 msec; echo time, 30 msec) was made, with a 1.5-T
unit (Somatom Plus; Siemens, Erlangen, Germany), at the facet
joint level of the lesion for each patient. The maximum thickness of the ligamentum flavum was traced with use of the manual cursor technique and was computed automatically by the
installed software in the magnetic resonance imaging scanner.
All of the radiographic analyses were independently performed
by two experienced spine surgeons who were not involved in
the care of the patients. Each observer independently measured
the thickness of the ligamentum flavum twice, and the average
of the four measurements was used as the final thickness.
Quantification of TIMP-1 and
TIMP-2 Concentrations by ELISA
After thawing, 100 mg of the ligamentum flavum tissue was homogenized with phosphate-buffered saline solution at 3000 rpm
in a tissue homogenizer (model 985-370, Tissue-Tearor; BioSpec Products, Racine, Wisconsin). Centrifugation to 15,000
rpm was then performed at 4°C for thirty minutes, and the supernatant was obtained. Quantification of protein was performed according to Bradford’s method27 with use of a protein
assay kit (catalogue number 500-0006; Bio-Rad Laboratories,
Hercules, California), and optical density was measured at 595
nm with a spectrophotometer (Ultrospec 3000; Pharmacia Biotech, Cambridge, United Kingdom) and adjusted equally to levels of 0.5 mg/mL (total protein concentration) for each sample.
TIMP-1 and TIMP-2 concentrations were measured
twice in each sample with use of an ELISA kit with antibodies
that recognize human TIMP-1 and TIMP-2 (R and D Systems,
Minneapolis, Minnesota); the kit was used according to the
manufacturer’s instructions. The average of the two measurements was considered to be the final concentration. For calibration, we used human recombinant TIMP-1 and TIMP-2
provided by the supplier to construct a standard curve and to
obtain absolute values.
Apoptosis: Analysis with In Situ
Nick End-Labeling (TUNEL) Assay
In situ terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end-labeling (TUNEL) reaction was
performed with use of a TACS 2 TdT DAB In Situ Apoptosis
Detection Kit (Trevigen, Gaithersburg, Maryland) according to
the manufacturer’s instructions. One section (4 µm thick) was
treated with proteinase K. Endogenous peroxidase was removed
with 2% H2O2. The 3′-OH ends of the fragmented DNA were
marked with TdT dNTP and divalent cation by adding TdT.
Two pathologists, who were unaware of the clinical data, were
responsible for counting total and TUNEL-positive ligamentum
flavum fibroblasts under ten randomly selected high-power
fields (×400). The apoptosis index was calculated as TUNEL-
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Fig. 1-A

Fig. 1-B

Immunohistochemical studies showing fibroblasts within the ligamentum flavum that are positively stained (arrows) for TIMP-1 (Fig. 1-A) and TIMP-2 (Fig. 1-B) (×400).

positive cells/total cells × 100%. Human tonsil tissue was used
as a positive control.
Cellular Proliferation: Analysis with
Immunohistochemistry for TIMPs and Ki-67
Ki-67, a cellular proliferation marker, was assayed to determine

if there was evidence of proliferation of ligamentum flavum fibroblasts. Three consecutive 4-µm-thick sections were cut on a
microtome, deparaffinized in xylene, and rehydrated. To determine the expression of TIMP-1, TIMP-2, and Ki-67, the avidin-biotin-peroxidase complex method and a Histostain-plus
SP kit (Zymed Laboratories, South San Francisco, California)
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Fig. 2-A

TUNEL-positive fibroblasts (arrows) were identified in samples of ligamentum flavum from patients with spinal stenosis (×400).

were used according to the manufacturer’s instructions. Purified mouse monoclonal antibodies to TIMP-1 and TIMP-2
(NeoMarkers, Fremont, California) and Ki-67 (DakoCytomation, Glostrup, Denmark) were used for this study at an optimum dilution of 1:20, 1:50, and 1:75, respectively. A human
breast carcinoma and a human colon carcinoma were used as

positive controls for TIMP-1 and TIMP-2, and tonsil tissue was
used for Ki-67.
Statistical Analysis
The independent-sample t test was used to compare the patients
with lumbar spinal stenosis and those with disc herniation in

Fig. 2-B

Human tonsil tissue was used as a positive control.
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Fig. 3-A

Immunohistochemical study showing that the fibroblasts within the ligamentum flavum are not
stained with Ki-67 (×400).

terms of the patients’ age, TIMP-1 and TIMP-2 concentrations,
ligamentum flavum thickness, and apoptosis index. The relationship between the TIMP concentration and the thickness of the
ligamentum flavum was determined with the Pearson correlation
test. A p value of <0.05 was considered to be significant.

Results
Thickness of the Ligamentum Flavum
he mean thickness of the ligamentum flavum (and standard deviation) was 5.68 ± 1.02 mm (range, 4.5 to 7.2 mm)
in the patients with lumbar spinal stenosis and 2.70 ± 0.35 mm

T

Fig. 3-B

Human tonsil tissue was used as a positive control.
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TABLE I Comparison of the Thickness of Ligamentum Flavum and the Concentrations of TIMP-1 and TIMP-2 Between the
Patients with Lumbar Spinal Stenosis and Those with Disc Herniation
Spinal
Stenosis* (N = 30)

Lumbar Disc
Herniation* (N = 30)

P Value

Ligamentum flavum thickness

5.68 ± 1.02 mm

2.70 ± 0.35 mm

<0.001†

Concentration of TIMP-1

6.33 ± 2.81 ng/mL

4.55 ± 2.06 ng/mL

0.081

Concentration of TIMP-2

12.62 ± 3.47 ng/mL

8.85 ± 4.33 ng/mL

0.028†

*The values are given as the mean and standard deviation. †The value was determined to be significant with the independent-sample t test.

(range, 2.2 to 3.3 mm) in those with lumbar disc herniation.
The difference was significant (p < 0.001) (Table I).

ation marker), suggesting that fibroblasts were not proliferating in any of the samples (Figs. 3-A and 3-B).

TIMP-1 and 2 Concentrations
With the number of samples available, there was no significant
difference in the mean concentration of TIMP-1 between the
patients with lumbar spinal stenosis (6.33 ± 2.81 ng/mL) and
those with lumbar disc herniation (4.55 ± 2.06 ng/mL) (p =
0.08) (Table I). In contrast, the difference between the mean
concentration of TIMP-2 in the patients with lumbar spinal
stenosis (12.62 ± 3.47 ng/mL; range, 6.9 to 19.1 ng/mL) and
that in the patients with disc herniation (8.85 ± 4.33 ng/mL;
range, 4.3 to 12.6 ng/mL) was significant (p = 0.028) (Table I).
Fibroblasts in the ligamentum flavum of both groups of patients showed positive cytoplasmic staining for TIMP-1 and
TIMP-2 (Figs. 1-A and 1-B).

Discussion
here are four types of tissue inhibitors of matrix metalloproteinase (TIMP-1 through 4). They bind strongly but
noncovalently to activated MMPs (matrix metalloproteinases),
enzymes that digest proteins in the extracellular matrix. TIMPs
are co-expressed with the MMPs and contribute to the regulation of their local activity so that increases in TIMP levels reduce MMP activity. Decreased MMP activity impairs matrix
degradation, which has been demonstrated to be associated
with fibrotic diseases. As the activity of MMPs is regulated by
specific TIMPs, the imbalance between MMPs and TIMPs is
thought to be an important determinant of extracellular matrix
deposition and breakdown. TIMPs also have other important
biological functions, including promotion of cellular proliferation and inhibition of apoptosis (programmed cell death) in a
wide range of cell types.
On the basis of this information, we postulated that
TIMPs may also play a role in the ligamentum flavum hypertrophy associated with lumbar stenosis, which is characterized by
increased extracellular matrix and fibrosis in the ligamentum.
We also hypothesized that TIMPs might influence ligamentum
hypertrophy by increasing proliferation and decreasing apoptosis of the ligamentum fibroblasts. To test our hypotheses, we
measured the concentrations of TIMP-1 and TIMP-2 in ligamentum flavum tissues from patients with lumbar spinal stenosis and compared them with those from a gender-matched
group of patients who had lumbar disc herniation.
We found that the TIMP-2 concentration was significantly (1.43-fold) higher in the patients with spinal stenosis
than it was in those with disc herniation (p = 0.028), and a significant association was observed between the TIMP-2 concentration and the thickness of the ligamentum flavum (p =
0.003). The TIMP-1 concentration in the patients with spinal
stenosis was also positively associated with the thickness of the
ligamentum flavum (p = 0.015). In addition, TIMP-1 and 2
were positively stained in the cytoplasm of ligamentum flavum fibroblasts. These results suggest that increased expression of TIMPs, especially TIMP-2, in ligamentum flavum
fibroblasts may be associated with hypertrophy of the ligamentum flavum in spinal stenosis.
We had theorized that TIMPs might play a role in steno-

Correlation Between TIMP Concentration
and Ligamentum Thickness
The Pearson correlation test showed a positive correlation between the TIMP-2 concentration and the thickness of the ligamentum flavum (correlation coefficient = 0.631, p = 0.003) and
between the TIMP-1 concentration and the thickness of the ligamentum flavum (correlation coefficient = 0.534, p = 0.015).
Apoptosis of Ligamentum Flavum Cells
There was a mean of 35.7 ± 18.4 total ligamentum flavum fibroblasts and 21.0 ± 10.7 TUNEL-positive ligamentum flavum fibroblasts per ten high-power fields (×400) in the
specimens from the patients with spinal stenosis; the apoptosis index was 58.8% ± 18.3% (Figs. 2-A and 2-B). The specimens from the patients with disc herniation showed a mean of
53.1 ± 17.7 total and 14.1 ± 5.63 TUNEL-positive ligamentum
flavum fibroblasts per ten high-power fields, and the apoptosis index was 26.6% ± 21.3%. The apoptosis index was significantly higher for the group with lumbar spinal stenosis than it
was for the group with disc herniation (p < 0.001), which disproved our theory that ligamentum flavum hypertrophy was
due to a decrease in cell death.
Fibroblast Proliferation in the Ligamentum Flavum
None of the fibroblasts within the ligamentum flavum samples from the patients with spinal stenosis or from those with
disc herniation stained positively with Ki-67 (cellular prolifer-
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sis by decreasing the rate at which fibroblasts undergo programmed cell death, resulting in increased cellularity. We
found that the expression of intracellular TIMP-2 in the ligamentum flavum fibroblasts was higher in the patients with
spinal stenosis than in the patients with disc herniation. However, contrary to our hypothesis, the programmed death rate
of fibroblasts was significantly higher and the number of total
cells was lower in the patients with spinal stenosis than they
were in those with disc herniation. These findings suggest that
the ligamentum flavum hypertrophy in spinal stenosis is not
caused by an increase in cell number resulting from a delay in
cell death. Furthermore, these results suggest that TIMPs do
not have the biologic function of inhibiting apoptosis of ligamentum flavum fibroblasts.
We had also theorized that TIMPs might play a role in
ligamentum flavum hypertrophy not just by decreasing cell
death, but also by inducing fibroblastic cell proliferation. We
utilized the Ki-67 antigen, a nuclear protein, which is preferentially expressed during all active phases of the cell cycles (G1,
S, G2, and M-phase) as well as mitosis but is absent in resting
cells (G0-phase). The antigen is rapidly degraded as the cell enters the nonproliferative state. Therefore, the Ki-67 antigen is
accepted as an excellent marker for cellular proliferation.
Again, contrary to our hypothesis, the ligamentum flavum fibroblasts from the patients with spinal stenosis and those with
disc herniation tested negative for the Ki-67 antigen, suggesting that they were not proliferating. These results suggest that
TIMPs do not have the biologic function of inducing proliferation of ligamentum flavum fibroblasts.
Few authors have investigated the biochemical etiology
of ligamentum flavum hypertrophy. We previously demonstrated the expression of transforming growth factor-beta 1
(TGF-β1) in ligamentum flavum fibroblasts and found that
the concentration was significantly higher in patients with spinal stenosis than it was in patients with disc herniation28. In an
in vitro study, Nakatani et al. found that mechanical stretching
force promotes collagen synthesis by cultured cells from human ligamentum flavum tissues through increased TGF-β1
production29. These studies support our finding that TGF-β1
can influence the expression of both MMPs and TIMPs30,31. Together, these studies suggest that biochemical as well as mechanical factors should be considered as possible etiologies of
ligamentum flavum hypertrophy in lumbar spinal stenosis.
As with any investigation, our study had limitations. First,
the patients with spinal stenosis were significantly older than
those with disc herniation. Therefore, we cannot exclude the
possibility that the natural aging process had an impact on the
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hypertrophy of the ligamentum flavum or on the other variables
that we measured in this study. In other words, some (perhaps
all) of the changes that were noted in our study could have simply been related to age. Second, it is not known whether the increased concentration of TIMP-2 in the patients with spinal
stenosis was a local or systemic phenomenon. To address this issue, we are currently in the process of comparing serum TIMP-1
and TIMP-2 concentrations in patients with lumbar spinal
stenosis with those concentrations in normal healthy volunteers.
In conclusion, the increased expression of TIMPs, especially TIMP-2, in ligamentum flavum fibroblasts might result
in fibrosis and hypertrophy of the ligamentum flavum in spinal stenosis by inhibiting MMP activity, but not by causing
proliferation of ligamentum flavum fibroblasts or inhibiting
apoptosis of ligamentum flavum fibroblasts. Gaining insights
into the biochemical pathophysiology of ligamentum flavum
hypertrophy might elucidate novel noninvasive therapeutic
approaches to the treatment of spinal stenosis. 
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